<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1302233246
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Licarb
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LITHIUM CARBONATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        100.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; III" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – III
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        QN05AN01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of acute manic and mixed episodes in patients 7 years and older</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Maintenance treatment in patients 7 years and older</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Before taking Lithium or Lithium Carbonate, tell your healthcare provider if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have heart problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have breathing problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have thyroid problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are pregnant or plan to become pregnant. Lithium and Lithium Carbonate may harm your unborn baby.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are breastfeeding or plan to breastfeed. Lithium and Lithium Carbonate can pass into your breastmilk and may harm your baby. You should not breastfeed during treatment with Lithium or Lithium Carbonate. Talk to your healthcare provider about the best way to feed your baby if you take Lithium or Lithium Carbonate.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take your Lithium and Lithium Carbonate exactly as prescribed by your healthcare provider.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your healthcare provider will do certain blood tests before starting and during treatment with Lithium and Lithium Carbonate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your healthcare provider may change your dose if needed. <strong>Do not </strong>change your dose on your own.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not </strong>double your dose if a dose is missed. Talk with your healthcare provider if you miss a dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not </strong>stop taking Lithium or Lithium Carbonate suddenly without talking to your healthcare provider.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your healthcare provider may change your Lithium or Lithium Carbonate dose to make sure you are taking the dose that is right for you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take too much Lithium or Lithium Carbonate, call your healthcare provider or poison control center, or go to the nearest hospital emergency room right away. In case of poisoning, call your poison control center at 1-800-2221222.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>kidney problems. </strong>People who take Lithium or Lithium Carbonate may have to urinate often (polyuria) and have other kidney problems that may affect how their kidneys work. These problems can happen within a few weeks of starting to take Lithium or Lithium Carbonate or after taking Lithium or Lithium Carbonate for a long time.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>low levels of sodium (salt) in your blood (hyponatremia). </strong>Lithium and Lithium Carbonate can cause you to lose sodium. Talk to your healthcare provider about your diet and how much fluid you are drinking when starting Lithium or Lithium Carbonate. If you have been sweating more than usual or have had diarrhea, you may need extra salt and more fluids. Talk to your healthcare provider if this happens.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>neurological problems</strong>. People who take Lithium or Lithium Carbonate with certain other medicines called antipsychotics may have symptoms such as weakness, tiredness, fever, tremors, and confusion. Talk to your healthcare provider if this happens. Ask if you are not sure about the medicines you take.</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>serotonin syndrome. </strong>A potentially life-threatening problem called serotonin syndrome can happen when you take Lithium or Lithium Carbonate while you take certain medicines called serotonergic and MAOIs. Symptoms of serotonin syndrome include:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; agitation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coma</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle twitching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seeing things that are not there</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rapid pulse</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tremors</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; become unstable</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high or low blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flushing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stiff muscles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizures</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thyroid problems.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>high calcium levels in your blood (hypercalcemia) and changes in your parathyroid gland(hyperparathyroidism) </strong>that may not go away when you stop taking Lithium or Lithium Carbonate.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>heart problems. </strong>People who take Lithium or Lithium Carbonate may find out they also have a heart problem called Brugada Syndrome. People who have unexplained fainting or who have a family history of sudden unexplained death before 45 years of age may have Brugada Syndrome and not know it. If you faint or feel abnormal heartbeats, talk to your healthcare provider right away.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The most common side effects of Lithium and Lithium Carbonate, include:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adults with manic or mixed episodes of bipolar I disorder:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; hand trembling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; excessive urination</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; increased thirst</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; general discomfort when you start treatment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children 7 to 17 years of age with manic or mixed episodes of bipolar I disorder:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive urination</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thyroid problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hand trembling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive thirst</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty walking</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&nbsp;</p><p>&nbsp;</p><p>Reporting of side effects &nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can help provide more information on the safety of this medicine.</p><p><strong><em>&bull; </em></strong><strong>Saudi Arabia<em>:</em></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>o Other GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C. Store in the original container.</p><p>The expiry date refers to the last day of that month.</p><p>This medicine does not require any special storage conditions.</p><p>do not throw away any medicines via wastewater or household waste. ask your pharmacist how to throw away medicines you no longer use. these measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What </strong><strong>Licarb</strong><strong> </strong><strong>contains</strong></p><p><strong>Licarb 150 mg, 300 mg and 600 mg: </strong></p><p>The active substance is Lithium Carbonate.</p><p>Each capsule contains Lithium Carbonate USP 150 mg</p><p>Each capsule contains Lithium Carbonate USP 300 mg</p><p>Each capsule contains Lithium Carbonate USP 600 mg</p><p>&nbsp;</p><p><strong><u>Licarb 150 mg, 300 mg and 600 mg</u></strong><strong><u>:</u></strong></p><p>&nbsp;</p><p>Talc USP (Luzenac pharma) and Empty hard gelatin capsule shells, size &#39;1&#39;, White/White Size &#39;4&#39; hard gelatin capsules and Pink/White Size &#39;OEL&#39; hard gelatin capsules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Licarb 150 mg:
White/White Size '4' hard gelatin capsules, imprinted with '97' on body and 'H' on cap, containing white to off-white powder.

Licarb 300 mg:
Pink/Pink size '1' hard gelatin capsules imprinted with '98' on body and 'H' on cap, containing white to off-white powder.
Licarb 600 mg:
Pink/White Size 'OEL' hard gelatin capsules, imprinted with '141' on body and 'H' on cap, containing white to off-white powder.

How supplied:
Licarb 150 mg, 300 mg and 600 mg capsules are supplied in Bottle pack.
Licarb 150 mg capsules – HDPE bottle of 100 Tablets.
Licarb 300 mg capsules – HDPE bottle of 100 Tablets.
Licarb 600 mg capsules – HDPE bottle of 100 Tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Saudi Amarox Industrial Company,</strong></p><p>Aljameah Street, Malaz quarter, Riyadh 11441</p><p>Saudi Arabia</p><p>Tel: +966 11 477 2215</p><p><strong>M</strong><strong>anufacturer</strong></p><p>Hetero Labs Limited Unit-III</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                09/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج نوبات الهوس الحادة والمختلطة لدى المرضى 7 سنوات فما فوق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاج الوقائي للمرضى 7 سنوات فما فوق</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قبل تناول الليثيوم أو كربونات الليثيوم ، أخبر مقدم الرعاية الصحية الخاص بك إذا كنت تعاني من الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل في الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل في القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل في الغدة الدرقية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حامل أو تخططين للحمل. قد يؤذي الليثيوم وكربونات الليثيوم الجنين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرضاعة الطبيعية أو التخطيط للرضاعة الطبيعية. يمكن أن ينتقل الليثيوم وكربونات الليثيوم إلى حليب الأم وقد يؤذي طفلك. يجب عدم الإرضاع أثناء العلاج باستخدام كربونات الليثيوم أو الليثيوم. تحدث إلى مقدم الرعاية الصحية الخاص بك حول أفضل طريقة لإطعام طفلك إذا كنت تتناول كربونات الليثيوم أو الليثيوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>طريقة تناول كبسولات ليكارب</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول الليثيوم وكربونات الليثيوم تمامًا كما هو موصوف من قبل مقدم الرعاية الصحية الخاص بك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقوم مقدم الرعاية الصحية الخاص بك بإجراء فحوصات دم معينة قبل بدء العلاج باستخدام الليثيوم وكربونات الليثيوم وأثناءه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يغير مقدم الرعاية الصحية جرعتك إذا لزم الأمر. لا تغير جرعتك بنفسك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا فاتتك جرعة<strong> لا تضاعف</strong> الجرعة لتعويض الجرعة المنسية. تحدث مع مقدم الرعاية الصحية الخاص بك إذا فاتتك جرعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا تتوقف</strong> عن تناول كربونات الليثيوم أو الليثيوم فجأة دون التحدث إلى مقدم الرعاية الصحية الخاص بك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يقوم مقدم الرعاية الصحية الخاص بك بتغيير جرعة الليثيوم أو كربونات الليثيوم للتأكد من أنك تتناول الجرعة المناسبة لك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تناولت جرعة زائدة من كربونات الليثيوم أو الليثيوم ، فاتصل بمقدم الرعاية الصحية أو مركز مراقبة السموم أو اذهب إلى أقرب غرفة طوارئ في المستشفى على الفور. في حالة التسمم ، اتصل بمركز مكافحة السموم على الرقم 1-800-2221222.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>&bull;&nbsp;&nbsp; &nbsp;مشاكل في الكلى: قد يضطر الأشخاص الذين يتناولون كربونات الليثيوم أو الليثيوم إلى التبول كثيرًا (تعدد البيلات) وإذا كان لديهم مشاكل أخرى في الكلى فقد تؤثر على طريقة عمل الكلى لديهم. يمكن أن تحدث هذه المشكلات في غضون أسابيع قليلة من بدء تناول كربونات الليثيوم أو الليثيوم أو بعد تناول كربونات الليثيوم أو الليثيوم لفترة طويلة.</p><p>&bull;&nbsp;&nbsp; &nbsp;انخفاض مستويات الصوديوم (الملح) في الدم (نقص صوديوم الدم): يمكن أن يتسبب الليثيوم وكربونات الليثيوم في فقدان الصوديوم. تحدث إلى مقدم الرعاية الصحية الخاص بك عن نظامك الغذائي وكمية السوائل التي يجب أن تشربها عند بدء استخدام كربونات الليثيوم أو الليثيوم. إذا كنت تتعرق أكثر من المعتاد أو أصبت بالإسهال ، فقد تحتاج إلى ملح إضافي ومزيد من السوائل. تحدث إلى مقدم الرعاية الصحية الخاص بك إذا حدث هذا.</p><p>&bull;&nbsp;&nbsp; &nbsp;مشاكل عصبية: قد يعاني الأشخاص الذين يتناولون كربونات الليثيوم أو الليثيوم مع بعض الأدوية الأخرى التي تسمى مضادات الذهان من أعراض مثل الضعف والتعب والحمى والرعشة والارتباك. تحدث إلى مقدم الرعاية الصحية الخاص بك إذا حدث هذا. اسأل عما إذا كنت غير متأكد من الأدوية التي تتناولها.</p><p>&bull;&nbsp;&nbsp; &nbsp;متلازمة السيروتونين: يمكن أن تحدث مشكلة تهدد الحياة تسمى متلازمة السيروتونين عندما تتناول كربونات الليثيوم أو الليثيوم أثناء تناول أدوية معينة تسمى هرمون السيروتونين و مثبطات أكسيداز أحادي الأمين ( MAOIs). تشمل أعراض متلازمة السيروتونين ما يلي:<br />&bull;&nbsp;&nbsp; &nbsp;الهياج<br />&bull;&nbsp;&nbsp; &nbsp;غيبوبة<br />&bull;&nbsp;&nbsp; &nbsp;دوار<br />&bull;&nbsp;&nbsp; &nbsp;حمى<br />&bull;&nbsp;&nbsp; &nbsp;أرتعاش العضلات<br />&bull;&nbsp;&nbsp; &nbsp;غثيان<br />&bull;&nbsp;&nbsp; &nbsp;رؤية أشياء غير موجودة<br />&bull;&nbsp;&nbsp; &nbsp;سرعة النبض<br />&bull;&nbsp;&nbsp; &nbsp;التعرق<br />&bull;&nbsp;&nbsp; &nbsp;الارتعاش<br />&bull;&nbsp;&nbsp; &nbsp;تصبح حالتك غير مستقرة<br />&bull;&nbsp;&nbsp; &nbsp;القيء<br />&bull;&nbsp;&nbsp; &nbsp;الالتباس<br />&bull;&nbsp;&nbsp; &nbsp;ارتفاع ضغط الدم أو انخفاضه<br />&bull;&nbsp;&nbsp; &nbsp;طفح جلدي<br />&bull;&nbsp;&nbsp; &nbsp;تصلب العضلات<br />&bull;&nbsp;&nbsp; &nbsp;النوبات<br />&bull;&nbsp;&nbsp; &nbsp;إسهال</p><p>&bull;&nbsp;&nbsp; &nbsp;مشاكل الغدة الدرقية.</p><p>&bull;&nbsp;&nbsp; &nbsp;ارتفاع مستويات الكالسيوم في الدم (فرط كالسيوم الدم) والتغيرات في الغدة الجار درقية (فرط نشاط جارات الدرقية) التي قد لا تختفي عند التوقف عن تناول الليثيوم أو كربونات الليثيوم.</p><p>&bull;&nbsp;&nbsp; &nbsp;مشاكل قلبية: قد يكتشف الأشخاص الذين يتناولون كربونات الليثيوم أو الليثيوم أنهم يعانون أيضًا من مشكلة في القلب تسمى متلازمة بروجادا. قد يعاني الأشخاص الذين يعانون من إغماء غير مبرر أو لديهم تاريخ عائلي من الموت المفاجئ غير المبرر قبل سن 45 عامًا من متلازمة بروجادا ولا يعرفون ذلك. إذا شعرت بالإغماء أو الشعور بضربات قلب غير طبيعية ، فتحدث إلى مقدم الرعاية الصحية الخاص بك على الفور.</p><p>تشمل الآثار الجانبية الأكثر شيوعًا لكربونات الليثيوم والليثيوم ما يلي:</p><p>&bull;&nbsp;&nbsp; &nbsp;البالغون المصابون بنوبات هوس أو أعراض مختلطة من الاضطراب ثنائي القطب من النوع الأول:<br />&bull;&nbsp;&nbsp; &nbsp;رجفة اليد<br />&bull;&nbsp;&nbsp; &nbsp;التبول المفرط<br />&bull;&nbsp;&nbsp; &nbsp;زيادة العطش<br />&bull;&nbsp;&nbsp; &nbsp;غثيان<br />&bull;&nbsp;&nbsp; &nbsp;شعور عام بعدم الراحة عند بدء العلاج</p><p>&bull;&nbsp;&nbsp; &nbsp;الأطفال الذين تتراوح أعمارهم بين 7 و 17 عامًا والذين يعانون من نوبات هوس أو مختلطة من الاضطراب ثنائي القطب من النوع الأول:</p><p>&bull;&nbsp;&nbsp; &nbsp;التبول المفرط<br />&bull;&nbsp;&nbsp; &nbsp;مشاكل الغدة الدرقية<br />&bull;&nbsp;&nbsp; &nbsp;رجفة اليد<br />&bull;&nbsp;&nbsp; &nbsp;العطش الشديد<br />&bull;&nbsp;&nbsp; &nbsp;دوار<br />&bull;&nbsp;&nbsp; &nbsp;طفح جلدي<br />&bull;&nbsp;&nbsp; &nbsp;صعوبة المشي<br />&bull;&nbsp;&nbsp; &nbsp;قلة الشهية<br />&bull;&nbsp;&nbsp; &nbsp;عدم وضوح الرؤية<br />&bull;&nbsp;&nbsp; &nbsp;غثيان<br />&bull;&nbsp;&nbsp; &nbsp;القيء<br />التبليغ عن الأعراض الجانبية<br />&nbsp;إذا زادت حدة أي من هذه الأعراض الجانبية ، أو لاحظت ظهور أعراض جانبية غير ما تم ذكره في هذه النشرة ، يرجى إبلاغ الطبيب المعالج أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه). بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء.&nbsp;<br />&nbsp;<br />دول مجلس التعاون الخليجي الأخرى:<br />&nbsp;يرجى الاتصال بالسلطة الصحية المختصة.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;احفظ هذا الدواء بعيدًا عن رؤية ومتناول أيدي الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن يحفظ في درجة حرارة أقل من 30 درجة مئوية كما يجب التخزين في العلبة الأصلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هذا الدواء لا يتطلب أي شروط تخزين خاصة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما يحتويه ليكارب كبسولات</strong></p><p dir="RTL">ليكارب 150 ملغم ، 300 ملغم و 600 ملغم:</p><p dir="RTL">المادة الفعالة هي كربونات الليثيوم.</p><p dir="RTL">تحتوي كل كبسولة ليكارب 150 ملغم على كربونات الليثيوم 150 ملغم المتوافق مع دستور الأدوية الأمريكي.</p><p dir="RTL">تحتوي كل كبسولة ليكارب 300 ملغم على كربونات الليثيوم 300 ملغم المتوافق مع دستور الأدوية الأمريكي.</p><p dir="RTL">تحتوي كل كبسولة ليكارب 600 ملغم على كربونات الليثيوم 600 ملغم المتوافق مع دستور الأدوية الأمريكي.</p><p dir="RTL"><strong><u>الصواغات الأخرى (ليكارب 150 ملغم ، 300 ملغم و 600 ملغم):</u></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تلك بودر والمتوافق مع دستور الأدوية الأمريكي (Luzenac pharma) ، كبسولات الجيلاتين الصلبة الفارغة ، مقاس &#39;1&#39; ، كبسولات جيلاتينية صلبة باللون الأبيض / الأبيض مقاس &#39;4&#39; وكبسولات جيلاتينية صلبة باللون الوردي / الأبيض مقاس &#39;OEL&#39;.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف تبدو ليكارب؟</strong></p><p dir="RTL"><strong><u>ليكارب 150 ملغم:</u></strong></p><p dir="RTL">كبسولات جيلاتينية صلبة مقاس &#39;4&#39; بيضاء / بيضاء ، مطبوع عليها &#39;97&#39; على الجسم و &#39;H&#39; على الغطاء ، تحتوي على مسحوق أبيض إلى أبيض مصفر.</p><p dir="RTL"><strong><u>ليكارب 300 ملغم:</u></strong></p><p dir="RTL">كبسولات جيلاتينية صلبة مقاس &#39;1&#39; باللون الوردي / الوردي مطبوع عليها &#39;98&#39; على الجسم و &#39;H&#39; على الغطاء ، وتحتوي على مسحوق أبيض إلى أبيض مصفر.</p><p dir="RTL"><strong><u>ليكارب 600 ملغم:</u></strong></p><p dir="RTL">كبسولات جيلاتينية صلبة باللون الوردي / الأبيض مقاس &#39;OEL&#39; ، مطبوع عليها &#39;141&#39; على الجسم و &#39;H&#39; على الغطاء ، تحتوي على مسحوق أبيض إلى أبيض مصفر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف تتوفر</strong><strong>:</strong></p><p dir="RTL">يتم توفير كبسولات ليكارب 150 ملغم و 300 ملغم و 600 ملغم في عبوات بلاستيكية.</p><p dir="RTL">ليكارب 150 ملغم كبسولات - زجاجة البولي إيثيلين&nbsp;العالي الكثافة (HDPE) بها 100 كبسولة.</p><p dir="RTL">ليكارب 300 ملغم كبسولات - زجاجة البولي إيثيلين&nbsp;العالي الكثافة (HDPE) بها 100 كبسولة.</p><p dir="RTL">ليكارب 600 ملغم كبسولات - زجاجة البولي إيثيلين&nbsp;العالي الكثافة (HDPE) بها 100 كبسولة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شركة أماروكس السعودية الصناعية</strong></p><p>شارع الجامعة &ndash; الملز &ndash; الرياض 11441</p><p>المملكة العربية السعودية.</p><p dir="RTL">تليفون + 966 114772215:</p><p><strong>المصنع:</strong></p><p dir="RTL">شركة هتيرو لاب المحدودة وحدة-III</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            9/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Licarb (Lithium Carbonate Capsules USP 300 mg). 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains Lithium Carbonate USP 300 mg 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pink/Pink size '1' hard gelatin capsules imprinted with '98' on body and 'H' on cap, containing white to off-white powder. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lithium is a mood-stabilizing agent indicated as monotherapy for the treatment of bipolar I disorder:&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of acute manic and mixed episodes in patients 12 years and older</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Maintenance treatment in patients 12 years and older</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before initiating treatment with lithium, renal function, vital signs, serum electrolytes, and thyroid function should be evaluated. Concurrent medications should be assessed, and if the patient is a woman of childbearing potential, pregnancy status and potential should be considered.</p><p>Recommended Dosage</p><p>See Table 1 for dosage recommendations for acute and maintenance treatment of bipolar</p><p>I disorder in adult and pediatric patients (12 years and older).</p><p>Obtain serum lithium concentration assay after 3 days, drawn 12 hours after the last oral dose and regularly until patient is stabilized. Fine hand tremor, polyuria, and thirst may occur during initial therapy for the acute manic phase and may persist throughout treatment. Nausea and general discomfort may also appear during the first few days of lithium administration. These adverse reactions may subside with continued treatment, concomitant administration with food,</p><p>&nbsp;Lithium Carbonate Capsules 300 mg</p><p>or temporary reduction or cessation of dosage. Table 1. Lithium Dosing for Bipolar I Disorder</p><table border="0" cellspacing="0" cellpadding="0" style="width:638px"><tbody><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>Patient </strong></p><p><strong>Group </strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Formulation </strong></p></td><td rowspan="2" style="vertical-align:bottom"><p><strong>Starting </strong></p><p><strong>Dose </strong></p></td><td rowspan="2" style="vertical-align:bottom"><p><strong>Dose </strong></p><p><strong>Titration </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Acute Goal </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Maintenance Goal </strong></p></td></tr><tr><td style="vertical-align:top"><p>Serum</p><p>level</p></td><td style="vertical-align:top"><p>Usual</p><p>Dose</p></td><td style="vertical-align:top"><p>Serum</p><p>level</p></td><td style="vertical-align:top"><p>Usual</p><p>Dose</p></td></tr><tr><td style="vertical-align:top"><p>Adult and</p><p>Pediatric</p><p>Patients over 30 kg</p></td><td style="vertical-align:top"><p>Capsules</p></td><td style="vertical-align:top"><p>300 mg three</p><p>times daily</p></td><td style="vertical-align:top"><p>300 mg every 3 days</p></td><td rowspan="2" style="vertical-align:top"><p>0.8 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to</p><p>1.2</p><p>mEq/L</p></td><td style="vertical-align:bottom"><p>600 mg two to</p><p>three times daily</p></td><td rowspan="2" style="vertical-align:top"><p>0.8 to 1.0</p><p>mEq/L</p></td><td style="vertical-align:top"><p>300 to</p><p>600 mg two to</p><p>three times daily</p></td></tr><tr><td style="vertical-align:top"><p>Pediatric</p><p>Patients</p><p>20 to 30 kg</p></td><td style="vertical-align:top"><p>Capsules</p></td><td style="vertical-align:top"><p>300 mg twice daily</p></td><td style="vertical-align:top"><p>300 mg weekly</p></td><td style="vertical-align:top"><p>600 to 1500 mg</p><p>in divided doses daily</p></td><td style="vertical-align:bottom"><p>600 to 1200 mg</p><p>in divided doses daily</p></td></tr></tbody></table><p><strong>2.3 Serum Lithium Monitoring </strong></p><p>Blood samples for serum lithium determination should be drawn immediately prior to the next dose when lithium concentrations are relatively stable (i.e., 12 hours after the previous dose). Total reliance must not be placed on serum concentrations alone. Accurate patient evaluation requires both clinical and laboratory analysis.</p><p>In addition to regular monitoring of serum lithium concentrations for patients on maintenance treatment, serum lithium concentrations should be monitored after any change in dosage, concurrent medication (e.g., diuretics, non-steroidal anti-inflammatory drugs, renin-angiotensin system antagonists, or metronidazole), marked increase or decrease in routinely performed strenuous physical activity (such as an exercise program) and in the event of a concomitant disease <em>[See Boxed</em> <em>Warning, Warnings and Precautions (5.1), Drug Interactions (7.1)].</em></p><p>Patients abnormally sensitive to lithium may exhibit toxic signs at serum concentrations that are within what is considered the therapeutic range. Geriatric patients often respond to reduced dosage, and may exhibit signs of toxicity at serum concentrations ordinarily tolerated by other patients <em>[see Specific Populations (8.5)].</em></p><p><strong>2.4 Dosage Adjustments during Pregnancy and the Postpartum Period </strong></p><p>If the decision is made to continue lithium treatment during pregnancy, monitor serum lithium concentrations and adjust the dosage as needed in a pregnant woman because renal lithium clearance increases during pregnancy. Avoid sodium restriction or diuretic administration. To decrease the risk of postpartum lithium intoxication, decrease or discontinue lithium therapy two to three days before the expected delivery date to reduce neonatal concentrations and reduce the risk of maternal lithium intoxication due to the change in vascular volume which occurs during delivery. At delivery, vascular volume rapidly decreases and the renal clearance of lithium may decrease to pre-pregnancy concentrations. Restart treatment at the preconception dose when the patient is medically stable after delivery with careful monitoring of serum lithium concentrations</p><p><em>[see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)].</em></p><p><strong>2.5 Dosage Adjustments for Patients with Renal Impairment </strong></p><p>Start patients with mild to moderately impaired renal function (creatinine clearance 30 to 89 mL/min evaluated by Cockcroft-Gault) with dosages less than those for patients with normal renal function <em>[see Dosage and Administration</em> <em>(2.2)]</em>. Titrate slowly while frequently monitoring serum lithium concentrations and monitoring for signs of lithium toxicity. Lithium is not recommended for use in patients with severe renal impairment (creatinine clearance less than&nbsp;&nbsp; 30 mL/min evaluated by Cockcroft-Gault) <em>[see Use in Specific Populations (8.6)].</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lithium is contraindicated in patients with known hypersensitivity to any inactive ingredient in the lithium carbonate tablet or capsule or lithium citrate products 
•	Acute Lithium Toxicity  
•	Lithium-Induced Polyuria  
•	Hyponatremia  
•	Lithium-Induced Chronic Kidney Disease  
•	Encephalopathic Syndrome  
•	Serotonin Syndrome  
•	Hypothyroidism or Hyperthyroidism  
•	Hypercalcemia and Hyperparathyroidism  
•	Unmasking of Brugada Syndrome  
•	Pseudotumor Cerebri  

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Lithium Toxicity </strong>&nbsp;</p><p>The toxic concentrations for lithium (&ge;1.5 mEq/L) are close to the therapeutic range (0.8 to 1.2mEq/L). Some patients abnormally sensitive to lithium may exhibit toxic signs at serum concentrations that are considered within the therapeutic range. Lithium may take up to 24 hours to distribute into brain tissue, so occurrence of acute toxicity symptoms may be delayed.&nbsp;</p><p>Neurological signs of lithium toxicity range from mild neurological adverse reactions such as fine tremor, lightheadedness, lack of coordination, and weakness; to moderate manifestations like giddiness, apathy, drowsiness, hyperreflexia, muscle twitching, ataxia, blurred vision, tinnitus, and slurred speech; and severe manifestations such as clonus, confusion, seizure, coma, and death. In rare cases, neurological sequelae may persist despite discontinuing lithium treatment and may be associated with cerebellar atrophy. Cardiac manifestations involve electrocardiographic changes, such as prolonged QT interval, ST and T-wave changes and myocarditis. Renal manifestations include urine concentrating defect, nephrogenic diabetes insipidus, and renal failure. Respiratory manifestations include dyspnea, aspiration pneumonia, and respiratory failure. Gastrointestinal manifestations include nausea, vomiting, diarrhea, and bloating. No specific antidote for lithium poisoning is known<em><sub>..</sub></em></p><p>The risk of lithium toxicity is increased by:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recent onset of concurrent febrile illness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Concomitant administration of drugs which increase lithium serum concentrations by pharmacokinetic interactions or drugs affecting kidney function&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute ingestion</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impaired renal function</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Volume depletion or dehydration</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Significant cardiovascular disease</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in electrolyte concentrations (especially sodium and potassium)&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Monitor for signs and symptoms of lithium toxicity. If symptoms occur, decrease dosage or discontinue lithium treatment.</p><p>Lithium-Induced Polyuria &nbsp;</p><p>Chronic lithium treatment may be associated with diminution of renal concentrating ability, occasionally presenting as nephrogenic diabetes insipidus, with polyuria and polydipsia. The concentrating defect and natriuretic effect characteristic of this condition may develop within weeks of lithium initiation. Lithium can also cause renal tubular acidosis, resulting in hyperchloremic metabolic acidosis. Such patients should be carefully managed to avoid dehydration with resulting lithium retention and toxicity. This condition is usually reversible when lithium is discontinued, although for patients treated with long-term lithium, nephrogenic diabetes insipidus may be only partly reversible upon discontinuation of lithium. Amiloride may be considered as a therapeutic agent for lithium-induced nephrogenic diabetes insipidus.&nbsp;</p><p>Hyponatremia &nbsp;</p><p>Lithium can cause hyponatremia by decreasing sodium reabsorption by the renal tubules, leading to sodium depletion. Therefore, it is essential for patients receiving lithium treatment to maintain a normal diet, including salt, and an adequate fluid intake (2,500 to 3,000 mL) at least during the initial stabilization period. Decreased tolerance to lithium has also been reported to ensue from protracted sweating or diarrhea and, if such occur, supplemental fluid and salt should be administered under careful medical supervision and lithium intake reduced or suspended until the condition is resolved. In addition, concomitant infection with elevated temperatures may also necessitate a temporary reduction or cessation of medication.&nbsp;</p><p>Symptoms are also more severe with faster-onset hyponatremia. Mild hyponatremia (i.e., serum Na &gt; 120 mEq/L) can be asymptomatic. Below this threshold, clinical signs are usually present, consisting mainly of changes in mental status, such as altered personality, lethargy, and confusion. For more severe hyponatremia (serum Na &lt; 115 mEq/L), stupor, neuromuscular hyperexcitability, hyperreflexia, seizures, coma, and death can result. During treatment of hyponatremia, serum sodium should not be elevated by more than 10 to 12 mEq/L in 24 hours, or 18 mEq/L in 48 hours. In the case of severe hyponatremia where severe neurologic symptoms are present, a faster infusion rate to correct serum sodium concentration may be needed. Patients rapidly treated or with serum sodium &lt;120mEq/L are more at risk of developing osmotic demyelination syndrome (previously called central pontine myelinolysis). Occurrence is more common among patients with alcoholism, undernutrition, or other chronic debilitating illness. Common signs include flaccid paralysis, dysarthria. In severe cases with extended lesions patients may develop a locked-in syndrome (generalized motor paralysis). Damage often is permanent. If neurologic symptoms start to develop during treatment of hyponatremia, serum sodium correction should be suspended to mitigate the development of permanent neurologic damage.&nbsp;</p><p>Lithium-Induced Chronic Kidney Disease &nbsp;</p><p>The predominant form of chronic renal disease associated with long-term lithium treatment is a chronic tubulointerstitial nephropathy (CTIN). The biopsy findings in patients with lithium induced CTIN include tubular atrophy, interstitial fibrosis, sclerotic glomeruli, tubular dilation, and nephron atrophy with cyst formation. The relationship between renal function and morphologic changes and their association with lithium treatment has not been established. CTIN patients might present with nephrotic proteinuria (&gt;3.0g/dL), worsening renal insufficiency and/or nephrogenic diabetes insipidus. Postmarketing cases consistent with nephrotic syndrome in patients with or without CTIN have also been reported. The biopsy findings in patients with nephrotic syndrome include minimal change disease and focal segmental glomerulosclerosis. The discontinuation of lithium in patients with nephrotic syndrome has resulted in remission of nephrotic syndrome.&nbsp;</p><p>Kidney function should be assessed prior to and during lithium treatment. Routine urinalysis and other tests may be used to evaluate tubular function (e.g., urine specific gravity or osmolality following a period of water deprivation, or 24-hour urine volume) and glomerular function (e.g., serum creatinine, creatinine clearance, or proteinuria). During lithium treatment, progressive or sudden changes in renal function, even within the normal range, indicate the need for&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; re-evaluation of treatment.&nbsp;</p><p>Encephalopathic Syndrome &nbsp;</p><p>An encephalopathic syndrome, characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN and fasting blood glucose, has occurred in patients treated with lithium and an antipsychotic. In some instances, the syndrome was followed by irreversible brain damage. Because of a possible causal relationship between these events and the concomitant administration of lithium and antipsychotics, patients receiving such combined treatment should be monitored closely for early evidence of neurological toxicity and treatment discontinued promptly if such signs appear. This encephalopathic syndrome may be similar to or the same as neuroleptic malignant syndrome (NMS).&nbsp;</p><p>Serotonin Syndrome &nbsp;</p><p>Lithium can precipitate serotonin syndrome, a potentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants, fentanyl, tramadol, tryptophan, buspirone, and St. John&rsquo;s Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs&nbsp;</p><p>Serotonin syndrome signs and symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).&nbsp;</p><p>Monitor all patients taking lithium for the emergence of serotonin syndrome. Discontinue treatment with lithium and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms.&nbsp;</p><p>Hypothyroidism or Hyperthyroidism&nbsp;</p><p>Lithium is concentrated within the thyroid and can inhibit thyroid synthesis and release which can lead to hypothyroidism. Where hypothyroidism exists, careful monitoring of thyroid function during lithium stabilization and maintenance allows for correction of changing thyroid parameters, if any. Where hypothyroidism occurs during lithium stabilization and maintenance, supplemental thyroid treatment may be used. Paradoxically, some cases of hyperthyroidism have been reported including Grave&rsquo;s disease, toxic multinodular goiter and silent thyroiditis.&nbsp;</p><p>Monitor thyroid function before the initiation of treatment, at three months and every six to twelve months while treatment is ongoing. If serum thyroid tests warrant concern, monitoring should occur more frequently.&nbsp;</p><p>Hypercalcemia and Hyperparathyroidism &nbsp;</p><p>Long-term lithium treatment is associated with persistent hyperparathyroidism and hypercalcemia. When clinical manifestations of hypercalcemia are present, lithium withdrawal and change to another mood stabilizer may be necessary. Hypercalcemia may not resolve upon discontinuation of lithium, and may require surgical intervention. Lithium-induced cases of hyperparathyroidism are more often multiglandular compared to standard cases. False hypercalcemia due to plasma volume depletion resulting from nephrogenic diabetes insipidus should be excluded in individuals with mildly increased serum calcium. Monitor serum calcium concentrations regularly.&nbsp;</p><p>Unmasking of Brugada Syndrome &nbsp;</p><p>There have been postmarketing reports of a possible association between treatment with lithium and the unmasking of Brugada Syndrome. Brugada Syndrome is a disorder characterized by abnormal electrocardiographic (ECG) findings and a risk of sudden death. Lithium should be avoided in patients with Brugada Syndrome or those suspected of having Brugada Syndrome. Consultation with a cardiologist is recommended if: (1) treatment with lithium is under consideration for patients suspected of having Brugada Syndrome or patients who have risk factors for Brugada Syndrome, e.g., unexplained syncope, a family history of Brugada Syndrome, or a family history of sudden unexplained death before the age of 45 years, (2) patients who develop unexplained syncope or palpitations after starting lithium treatment.&nbsp;</p><p>Pseudotumor Cerebri &nbsp;</p><p>Cases of pseudotumor cerebri (increased intracranial pressure and papilledema) have been reported with lithium use. If undetected, this condition may result in enlargement of the blind spot, constriction of visual fields and eventual blindness due to optic atrophy. Consider discontinuing lithium if this syndrome occurs.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Drugs Having Clinically Important Interactions with Lithium&nbsp; Table 4: Clinically Important Drug Interactions with Lithium&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:637px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Diuretics </strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Clinical Impact:&nbsp;</p></td><td style="vertical-align:top"><p>Diuretic-induced sodium loss may reduce lithium clearance and increase serum lithium concentrations.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Intervention:&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>More frequent monitoring of serum electrolyte and lithium concentrations. Reduce lithium dosage based on serum lithium concentration and clinical response&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Examples:&nbsp;</p></td><td style="vertical-align:top"><p>hydrochlorothiazide, chlorothiazide, furosemide&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Non-Steroidal Anti-inflammatory Drugs (NSAID) </strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Clinical Impac</p></td><td style="vertical-align:top"><p>t NSAID decrease renal blood flow, resulting in decreased renal clearance and</p><p>increased serum lithium concentrations.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Intervention:&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>More frequent serum lithium concentration monitoring. Reduce lithium dosage based on serum lithium concentration and clinical response.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Examples:&nbsp;</p></td><td style="vertical-align:top"><p>indomethacin, ibuprofen, naproxen&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renin-Angiotensin System Antagonists </strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Clinical Impac</p></td><td style="vertical-align:top"><p>t Concomitant use increase steady-state serum lithium concentrations.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Intervention:&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>More frequent monitoring of serum lithium concentration. Reduce lithium dosage based on serum lithium concentration and clinical response.</p></td></tr><tr><td style="vertical-align:top"><p>Examples:&nbsp;</p></td><td style="vertical-align:top"><p>lisinopril, enalapril, captopril, valsartan&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Serotonergic Drugs </strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Clinical Impac</p></td><td style="vertical-align:top"><p>t Concomitant use can precipitate serotonin syndrome.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Intervention:&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Monitor patients for signs and symptoms of serotonin syndrome, particularly during lithium initiation. If serotonin syndrome occurs, consider discontinuation</p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0" style="width:637px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>of lithium and/or concomitant serotonergic drugs.</p></td></tr><tr><td style="vertical-align:top"><p>Examples:&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake inhibitors (SNRI), monoamine oxidase inhibitors (MAOI)&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nitroimidazole Antibiotics </strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Clinical Impac</p></td><td style="vertical-align:top"><p>t Concomitant use may increase serum lithium concentrations due to reduced renal</p><p>clearance.</p></td></tr><tr><td style="vertical-align:top"><p>Intervention:&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>More frequent monitoring of serum lithium concentration. Reduce lithium dosage based on serum lithium concentration and clinical response.</p></td></tr><tr><td style="vertical-align:top"><p>Examples:&nbsp;</p></td><td style="vertical-align:top"><p>metronidazole&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Acetazolamide, Urea, Xanthine Preparations, Alkalinizing Agents </strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Clinical Impac</p></td><td style="vertical-align:top"><p>t Concomitant use can lower serum lithium concentrations by increasing urinary</p><p>lithium excretion.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Intervention:&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>More frequent serum lithium concentration monitoring. Increase lithium dosage based on serum lithium concentration and clinical response.</p></td></tr><tr><td style="vertical-align:top"><p>Examples:&nbsp;</p></td><td style="vertical-align:top"><p>acetazolamide, theophylline, sodium bicarbonate&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Methyldopa, Phenytoin and Carbamazepine </strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Clinical Impac</p></td><td style="vertical-align:top"><p>t Concomitant use may increase risk of adverse reactions of these drugs&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Intervention:&nbsp;</p></td><td style="vertical-align:top"><p>Monitor patients closely for adverse reactions of methyldopa, phenytoin, and carbamazepine.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Iodide Preparations </strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Clinical Impact:&nbsp;</p></td><td style="vertical-align:top"><p>Concomitant use may produce hypothyroidism.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Intervention:&nbsp;</p></td><td style="vertical-align:top"><p>Monitor patients for signs or symptoms of hypothyroidism.</p></td></tr><tr><td style="vertical-align:top"><p>Examples:&nbsp;</p></td><td style="vertical-align:top"><p>potassium iodide&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Calcium Channel Blocking Agents (CCB) </strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Clinical Impac</p></td><td style="vertical-align:top"><p>t Concomitant use may increase the risk of neurologic adverse reactions in the</p><p>form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Intervention:&nbsp;</p></td><td style="vertical-align:top"><p>Monitor for neurologic adverse reactions.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Examples:&nbsp;</p></td><td style="vertical-align:top"><p>diltiazem, nifedipine, verapamil&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Atypical and Typical Antipsychotic Drugs </strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Clinical Impac</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>t Reports of neurotoxic reactions in patients treated with both lithium and an antipsychotic, ranging from extrapyramidal symptoms to neuroleptic malignant syndrome, as well as reports of an encephalopathic syndrome in few patients treated with concomitant therapy.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Intervention:&nbsp;</p></td><td style="vertical-align:top"><p>Monitor for neurologic adverse reactions.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Examples:&nbsp;</p></td><td style="vertical-align:top"><p>risperidone, &nbsp; haloperidol, &nbsp;&nbsp;&nbsp; thioridazine, &nbsp;&nbsp; fluphenazine, chlorpromazine, perphenazine, clozapine&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Neuromuscular Blocking Agents </strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Clinical Impac</p></td><td style="vertical-align:top"><p>t Lithium may prolong the effects of neuromuscular blocking agents.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Intervention:&nbsp;</p></td><td style="vertical-align:top"><p>Monitor for prolonged paralysis.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Examples:&nbsp;</p></td><td style="vertical-align:top"><p>succinylcholine, pancuronium&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Impairment of Fertility&nbsp;</p><p>There have been no adequate studies performed in animals at current standards to evaluate the effect of lithium treatment on fertility. However, published studies in male mice and rats administered repeated daily dosing of lithium carbonate report adverse effects on male reproductive organs, decreased spermatogenesis and decreased testosterone levels.&nbsp;</p><p>Risk Summary&nbsp;</p><p>Lithium may cause harm when administered to a pregnant woman. Early voluntary reports to international birth registries suggested an increase in cardiovascular malformations, especially for Ebstein&rsquo;s anomaly, with first trimester use of lithium. Subsequent case-control and cohort studies indicate that the increased risk for cardiac malformations is likely to be small; however, the data are insufficient to establish a drug-associated risk. There are concerns for maternal and/or neonatal lithium toxicity during late pregnancy and the postpartum period [see Clinical Considerations]. Published animal developmental and toxicity studies in mice and rats report an increased incidence of fetal mortality, decreased fetal weight, increased fetal skeletal abnormalities, and cleft palate (mouse fetuses only) with oral doses of lithium that produced serum concentrations similar to the human therapeutic range. Other published animal studies <u>report adverse effects on embryonic implantation in rats after lithium administration. Advis</u>e</p><p>&nbsp;Lithium Carbonate Capsules 300 mg</p><p>pregnant women of the potential risk to a fetus.</p><p>The background risk of major birth defects and miscarriage for the indicated population(s) is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.&nbsp;</p><p>Clinical Considerations</p><p><u>Dose Adjustments During Pregnancy and the Postpartum Period:</u> If the decision is made to continue lithium treatment during pregnancy, serum lithium concentrations should be monitored and the dosage adjusted during pregnancy. Two to three days prior to delivery, lithium dosage should be decreased or discontinued to reduce the risk of maternal and/or neonatal toxicity. Lithium may be restarted in the post-partum period at preconception doses in medically stable patients as long as serum lithium levels are closely monitored.&nbsp;</p><p><u>Fetal/Neonatal Adverse Reactions:</u> Lithium toxicity may occur in neonates who were exposed to lithium in late pregnancy. A floppy baby syndrome including neurological, cardiac, and hepatic abnormalities that are similar to those seen with lithium toxicity in adults have been observed. Symptoms include hypotonia, respiratory distress syndrome, cyanosis, lethargy, feeding difficulties, depressed neonatal reflexes, neonatal depression, apnea, and bradycardia. Monitor neonates and provide supportive care until lithium is excreted and toxic signs disappear, which may take up to 14 days.&nbsp;</p><p>Consider fetal echocardiography between 16 and 20 weeks gestation in a woman with first trimester lithium exposure because of the potential increased risk of cardiac malformations. <u>Risk Summary</u>&nbsp;</p><p>Limited published data reports the presence of lithium carbonate in human milk with breast milk levels measured at 0.12 to 0.7 mEq or 40 to 45% of maternal plasma levels. Infants exposed to lithium during breastfeeding may have plasma levels that are 30 to 40% of maternal plasma levels. Signs and symptoms of lithium toxicity such as hypertonia, hypothermia, cyanosis, and ECG changes have been reported in some breastfed neonates and infants. Increased prolactin levels have been measured in lactating women, but the effects on milk production are not known. Breastfeeding is not recommended with maternal lithium use; however, if a woman chooses to breastfeed, the infant should be closely monitored for signs of lithium toxicity. Discontinue</p><p>&nbsp;Lithium Carbonate Capsules 300 mg</p><p>breastfeeding if a breastfed infant develops lithium toxicity.&nbsp;</p><p>Clinical Considerations&nbsp;</p><p>Consider regular monitoring of lithium levels and thyroid function in a breastfed infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy: May cause fetal and/or neonatal harm&nbsp;</p><p>Renal Impairment: Use caution during dose selection, starting with dosages less than those for patients with normal renal function while carefully monitoring for side effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p><p><em>Pediatric Patients (12 years and older) </em></p><p><u>Bipolar I Disorder:</u> The following findings are based on an 8-week, placebo-controlled study for acute manic or mixed episodes of bipolar I disorder in pediatric patients 12 years and older (N= 81). In this study, lithium was administered at daily doses ranging from 300 to 3,600 (mean dose 1,483 mg &plusmn; 584) with serum levels ranging from 0 to 2.0 (mean level 0.98 mEq/L &plusmn; 0.47).</p><p><em><u>Common Adverse Reactions (incidence &ge; 5% and at least twice the rate of placebo):</u> </em>nausea/vomiting, polyuria, thyroid abnormalities, tremor, thirst/polydipsia, dizziness, rash/dermatitis, ataxia/gait disturbance, decreased appetite, and blurry vision.</p><p><em><u>Adverse Reactions Occurring at an Incidence of 2% or More in Lithium-Treated Pediatric</u> <u>Patients:</u> </em>Adverse reactions associated with the use of lithium (incidence of 2% or greater, rounded to the nearest percent, and lithium incidence greater than placebo) that occurred during acute therapy (up to 8-weeks in pediatric patients with bipolar disorder) are shown in Table.</p><p>Adverse Reactions Reported in 2% or More of Pediatric Patients on Lithium and That Occurred at Greater Incidence Than in the Placebo Group in the 8-Week Acute Bipolar Trial</p><table border="0" cellspacing="0" cellpadding="0" style="width:442px"><tbody><tr><td style="vertical-align:top"><p><strong>System</strong> <strong>Organ</strong> <strong>Class/ </strong></p><p><strong>Preferred Term</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong> <strong>N=28%</strong></p></td><td style="vertical-align:top"><p><strong>Lithium</strong> <strong>N=53%</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal</strong> <strong>Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea/vomiting</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>57</p></td></tr><tr><td style="vertical-align:top"><p><strong>General Disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Fatigue&nbsp;</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>26</p></td></tr><tr><td style="vertical-align:top"><p><strong>Genitourinary</strong> <strong>Disordres</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Polyuria (Including Enuresis)</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>38</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations&nbsp; </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Increased TSH</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>25</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism</strong> <strong>and</strong> <strong>nutrition</strong> <strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Thirst/polydipsia</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>28</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous</strong> <strong>system</strong> <strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Ataxia/gait disturbance</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>13</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Blurry vision</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Disorientation&nbsp;</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Dizziness&nbsp;</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>23</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Tremor&nbsp;</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>32</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin</strong> &nbsp;&nbsp; <strong>and</strong> &nbsp;&nbsp;&nbsp;&nbsp; <strong>subcutaneous</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>tissue</strong> <strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rash/dermatitis</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>13</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>Adult Patients </em></p><p>The following adverse reactions have been identified following use of lithium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. <em><sub>&nbsp;</sub></em></p><p><u>Central Nervous System</u>:<em><sub> </sub></em>tremor, muscle hyperirritability (fasciculations, twitching, clonic movements of whole limbs), hypertonicity, ataxia, choreoathetotic movements, hyperactive deep tendon reflexes, extrapyramidal symptoms including acute dystonia, cogwheel rigidity, blackout spells, epileptiform seizures, slurred speech, dizziness, vertigo, downbeat nystagmus, incontinence of urine or feces, somnolence, psychomotor retardation, restlessness, confusion, stupor, coma, tongue movements, tics, tinnitus, hallucinations, poor memory, slowed intellectual functioning, startled response, worsening of organic brain syndromes, myasthenic syndromes</p><p>(rarely).&nbsp;</p><p><u>EEG Changes:</u><em><sub> </sub></em>diffuse slowing, widening of frequency spectrum, potentiation and disorganization of background rhythm.</p><p><u>Cardiovascular</u>:<em><sub> </sub></em>conduction disturbance (mostly sinus node dysfunction with possibly severe sinus bradycardia and sinoatrial block), ventricular tachyarrhythmia, peripheral vasculopathy&nbsp;&nbsp; (resembling Raynaud&rsquo;s Syndrome).</p><p><u>ECG Changes:</u><em><sub> </sub></em>reversible flattening, isoelectricity or rarely inversion of T-waves, prolongation of the QTc interval.&nbsp;</p><p><u>Gastrointestinal:</u><em><sub> </sub></em>anorexia, nausea, vomiting, diarrhea, gastritis, salivary gland swelling, abdominal pain, excessive salivation, flatulence, indigestion.&nbsp;</p><p><u>Genitourinary</u>:<em><sub> </sub></em>glycosuria, decreased creatinine clearance, albuminuria, oliguria, and symptoms of nephrogenic diabetes insipidus including polyuria, thirst, and polydipsia.&nbsp;</p><p><u>Dermatologic:</u> drying and thinning of hair, alopecia, anesthesia of skin, chronic folliculitis, xerosis cutis, psoriasis onset or exacerbation, generalized pruritus with or without rash, cutaneous ulcers, angioedema.&nbsp;</p><p><u>Autonomic Nervous System</u><em><sub>: </sub></em>blurred vision, dry mouth, impotence/sexual dysfunction.&nbsp;</p><p><u>Miscellaneous</u><em><sub>: </sub></em>fatigue, lethargy, transient scotoma, exopthalmos, dehydration, weight loss, leukocytosis, headache, transient hyperglycemia, hypermagnesemia, excessive weight gain, edematous swelling of ankles or wrists, dysgeusia/taste distortion (e.g., metallic or salty taste), thirst, swollen lips, tightness in chest, swollen and/or painful joints, fever, polyarthralgia, and dental caries.<strong> </strong></p><p>Reporting of suspected adverse reactions</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below)</p><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><p><strong><em>&bull; </em>Saudi Arabia<em>: </em></strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o&nbsp; SFDA Call Center: 19999&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; o E-mail:npc.drug@sfda.gov.sa&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; o Website:https://ade.sfda.gov.sa/</p><p>o&nbsp; <strong>Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The toxic concentrations for lithium (&ge; 1.5 mEq/L) are close to the therapeutic concentrations [see Warnings and Precautions (5.1)]. At lithium concentrations greater than 3 mEq/L, patients may progress to seizures, coma, and irreversible brain damage.<br /><strong>Treatment: </strong></p><p>For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1800-222-1222 or www.poison.org.</p><p>No specific antidote for lithium poisoning is known. Mild symptoms of lithium toxicity can usually be treated by reduction in dose or cessation of the drug.</p><p>In severe cases of lithium poisoning, the goal of treatment is elimination of this ion from the patient. Administration of gastric lavage should be performed, but use of activated charcoal is not recommended as it does not significantly absorb lithium ions. Hemodialysis is the treatment of choice as it is an effective and rapid means of removing lithium in patients with severe toxicity. As an alternative option, urea, mannitol and aminophylline can induce a significant increase in lithium excretion. Appropriate supportive care for the patient should be undertaken. Patients with impaired consciousness should have their airway protected and it is critical to</p><p>correct any volume depletion or electrolyte imbalance. Patients should be monitored to prevent hypernatremia while receiving normal saline and careful regulation of kidney function is of utmost importance.</p><p>Serum lithium concentrations should be closely monitored as there may be a rebound in serum lithium concentrations as a result of delayed diffusion from the body tissues. Likewise, during the late recovery phase, lithium should be re-administered with caution taking into account the possible release of significant lithium stores in body tissues.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lithium is a mood-stabilizing agent indicated as monotherapy for the treatment of bipolar I disorder:</p><p>Treatment of acute manic and mixed episodes in patients 12 years and older</p><p>Maintenance treatment in patients 12 years and older</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>&nbsp;Absorption</u></p><p>After oral administration, lithium is reported to be completely absorbed in the upper gastrointestinal tract. Peak serum concentrations (T<sub>max</sub>) occur 0.25 to 3 hours after oral administration of immediate release preparations and 2 to 6 hours after sustained-release preparations.</p><p><u>Distribution</u></p><p>The distribution space of lithium approximates that of total body water, and the plasma protein binding is negligible. After equilibrium, the apparent volume of distribution is 0.7 to 1 L/kg.</p><p><u>Metabolism</u></p><p>Lithium is not metabolized.</p><p><u>Excretion</u></p><p>Lithium is primarily excreted in urine, proportionally to its serum concentration. Lithium is filtered by the glomerulus, and 80% is reabsorbed by passive diffusion in the proximal tubule. The elimination half-life of lithium is approximately 18 to 36 hours. Lithium excretion in feces is insignificant.</p><p>Specific Populations</p><p><u>Pediatric Use:</u> A pharmacokinetic study of lithium was performed in 39 subjects with bipolar I disorder. Both apparent clearance and apparent volume of distribution increase as body weight increases. A lower dose in patients &lt; 30 kg is necessary to achieve lithium exposures in pediatric patients similar to those observed in adults treated at recommended doses of lithium [see Dosage and Administration (2.2)]. The estimated plasma clearance was 0.59 L/h, 0.79 L/h and 1.17 L/h for pediatric patients weighing 20 kg, 30 kg and 50 kg, respectively.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p><p>Pediatric Patients (12 years and older)</p><p><u>Bipolar I Disorder:</u> The following findings are based on an 8-week, placebo-controlled study for acute manic or mixed episodes of bipolar I disorder in pediatric patients 12 years and older (N= 81). In this study, lithium was administered at daily doses ranging from 300 to 3,600 (mean dose 1,483 mg &plusmn; 584) with serum levels ranging from 0 to 2.0 (mean level 0.98 mEq/L &plusmn; 0.47).</p><p><u>Common Adverse Reactions (incidence &ge; 5% and at least twice the rate of placebo):</u> nausea/vomiting, polyuria, thyroid abnormalities, tremor, thirst/polydipsia, dizziness, rash/dermatitis, ataxia/gait disturbance, decreased appetite, and blurry vision.</p><p><u>Adverse Reactions Occurring at an Incidence of 2% or More in Lithium-Treated Pediatric</u> <u>Patients:</u> Adverse reactions associated with the use of lithium (incidence of 2% or greater, rounded to the nearest percent, and lithium incidence greater than placebo) that occurred during acute therapy (up to 8-weeks in pediatric patients with bipolar disorder) are shown in Table.</p><p>Adverse Reactions Reported in 2% or More of Pediatric Patients on Lithium and That Occurred at Greater Incidence Than in the Placebo Group in the 8-Week Acute Bipolar Trial</p><table border="0" cellspacing="0" cellpadding="0" style="width:489px"><tbody><tr><td style="vertical-align:top"><p><strong>System</strong> <strong>Organ</strong> <strong>Class/ Preferred Term</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong> <strong>N=28%</strong></p></td><td style="vertical-align:top"><p><strong>Lithium</strong> <strong>N=53%</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal</strong> <strong>Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea/vomiting</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>57</p></td></tr><tr><td style="vertical-align:top"><p><strong>General Disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Fatigue</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>26</p></td></tr><tr><td style="vertical-align:top"><p><strong>Genitourinary</strong> <strong>Disordres</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Polyuria (Including Enuresis)</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>38</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Increased TSH</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>25</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism</strong> <strong>and</strong> <strong>nutrition</strong> <strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Thirst/polydipsia</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>28</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous</strong> <strong>system</strong> <strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Ataxia/gait disturbance</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>13</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Blurry vision</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Disorientation</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>23</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Tremor</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>32</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin</strong> &nbsp;&nbsp; <strong>and</strong> &nbsp;&nbsp;&nbsp;&nbsp; <strong>subcutaneous</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>tissue</strong> <strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rash/dermatitis</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>13</p></td></tr></tbody></table><p>Adult Patients</p><p>The following adverse reactions have been identified following use of lithium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p><u>Central Nervous System</u>: tremor, muscle hyperirritability (fasciculations, twitching, clonic movements of whole limbs), hypertonicity, ataxia, choreoathetotic movements, hyperactive deep tendon reflexes, extrapyramidal symptoms including acute dystonia, cogwheel rigidity, blackout spells, epileptiform seizures, slurred speech, dizziness, vertigo, downbeat nystagmus, incontinence of urine or feces, somnolence, psychomotor retardation, restlessness, confusion, stupor, coma, tongue movements, tics, tinnitus, hallucinations, poor memory, slowed intellectual functioning, startled response, worsening of organic brain syndromes, myasthenic syndromes</p><p>(rarely).&nbsp;</p><p><u>EEG Changes:</u><em><sub> </sub></em>diffuse slowing, widening of frequency spectrum, potentiation and disorganization of background rhythm.</p><p><u>Cardiovascular</u>:<em><sub> </sub></em>conduction disturbance (mostly sinus node dysfunction with possibly severe sinus bradycardia and sinoatrial block), ventricular tachyarrhythmia, peripheral vasculopathy (resembling Raynaud&rsquo;s Syndrome).</p><p><u>ECG Changes:</u><em><sub> </sub></em>reversible flattening, isoelectricity or rarely inversion of T-waves, prolongation of the QTc interval.&nbsp;</p><p><u>Gastrointestinal:</u><em><sub> </sub></em>anorexia, nausea, vomiting, diarrhea, gastritis, salivary gland swelling, abdominal pain, excessive salivation, flatulence, indigestion.&nbsp;</p><p><u>Genitourinary</u>:<em><sub> </sub></em>glycosuria, decreased creatinine clearance, albuminuria, oliguria, and symptoms of nephrogenic diabetes insipidus including polyuria, thirst, and polydipsia.&nbsp;</p><p><u>Dermatologic:</u> drying and thinning of hair, alopecia, anesthesia of skin, chronic folliculitis, xerosis cutis, psoriasis onset or exacerbation, generalized pruritus with or without rash, cutaneous ulcers, angioedema.&nbsp;</p><p><u>Autonomic Nervous System</u><em><sub>: </sub></em>blurred vision, dry mouth, impotence/sexual dysfunction.</p><p><u>Miscellaneous</u><em><sub>: </sub></em>fatigue, lethargy, transient scotoma, exopthalmos, dehydration, weight loss, leukocytosis, headache, transient hyperglycemia, hypermagnesemia, excessive weight gain, edematous swelling of ankles or wrists, dysgeusia/taste distortion (e.g., metallic or salty taste), thirst, swollen lips, tightness in chest, swollen and/or painful joints, fever, polyarthralgia, and dental caries.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Talc (Luzenac pharma)&nbsp;</p><p>Empty Hard Gelatin Capsules composition: Gelatin, Titanium Dioxide, FD&amp;C Red<strong>&nbsp; </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>100&rsquo;s Count HDPE bottle pack<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Amarox Industrial Company, 
Aljameah Street, Malaz quarter,  
Riyadh 11441, Saudi Arabia Tel: +966 11 477 2215
Manufacture:  
Hetero Lab Unit III, Hyderabad, India  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                February-2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>